August 24, 2020 |
The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients. The tests on 70,000 people suggest that the blood transfusion can reduced COVID-19 mortality by 35%.
This procedure is transferring antibodies in the blood of people who were infected with COVID-19 and then recovered. The antibodies are given to people who are hospitalized with COVID-19.
Convalescent blood plasma therapy has been used since the 1880s and was used against the Spanish Flu.
SOURCES – FDA, Stat News
Written By Brian Wang, Nextbigfuture.com
Brian Wang is a futurist, speaker, and successful blogger who covers a wide range of bleeding edge science and technology topics. His blog at Nextbigfuture.com receives 5+ million annual readers and is ranked as the #1 Science News Blog worldwide by Alexa, an Amazon company. Brian covers disruptive technology trends including Space, Robotics, Artificial Intelligence, Quantum Computing, Medicine, Anti-aging Biotechnology, and Nanotechnology. His work has been cited by futurist, Peter Diamandis and by marketing guru Seth Godin. Being a future enthusiast himself, he is currently a startup co-founder, Angel Investor, as well as advisor to several technology companies. Prior to blogging and lecturing on the future, Brian was a founder & CEO of a multi-million dollar technology consulting firm designing IT systems. He received a BS in Computer Science from University of Regina, and MBA from University of Calgary.
